MIAMI LAKES, Fla.--(BUSINESS WIRE)--
ERBA Diagnostics, Inc. (NYSE MKT: ERB), a fully integrated in vitro diagnostics company, is pleased to announce ERBA Diagnostics will be attending the JP Morgan 32nd Annual Healthcare Conference in San Francisco, California from January 13-16, 2014. ERBA will be sharing a company presentation with some of the investors present at the conference and has filed an 8K with the presentation as an exhibit.
About the JP Morgan 32nd Annual Healthcare Conference
The conference is one of the largest and most informative healthcare investment symposiums in the industry, bringing together global industry leaders, emerging healthcare companies and members of the investment community. Approximately 300 companies and 4,000 investors are expected to attend the conference.
About ERBA Diagnostics, Inc.
ERBA Diagnostics, Inc. (www.erbadiagnostics.com), headquartered in Miami Lakes, Florida, is a fully integrated in vitro diagnostics company that develops, manufactures and distributes in the United States and internationally, proprietary diagnostic reagents, test kits and instrumentation, primarily for autoimmune and infectious diseases, clinical chemistry, hematology and diabetes through its six subsidiaries – Diamedix Corporation (U.S.), Delta Biologicals S.r.l. (Europe), ImmunoVision, Inc. (U.S.), Drew Scientific, Inc. (U.S.), JAS Diagnostics, Inc. (U.S.), and Erba Diagnostics Mexico S.A. (Latin America).
- Health Care Industry
- Investment & Company Information
Mohan Gopalkrishnan, 305-324-2300
Vice President - Operations